Current approach to muscle imaging in myositis.

Journal

Current opinion in rheumatology

ISSN: 1531-6963

Titre abrégé: Curr Opin Rheumatol

Pays: United States

ID NLM: 9000851

Informations de publication

Date de publication:
23 Aug 2024

Historique:

medline: 22 8 2024

pubmed: 22 8 2024

entrez: 22 8 2024

Statut: aheadofprint

Résumé

Muscle imaging is commonly utilized in idiopathic inflammatory myopathies (IIM) for diagnostic evaluation, selection of muscle biopsy site, and differentiating between disease activity versus damage. In this review, we discuss the current state and recent developments in the use of muscle imaging modalities including muscle magnetic resonance imaging (MRI), ultrasound (US), and positron emission tomography (PET) scan. Muscle MRI is a clinically useful tool in evaluation of IIM with studies showing good correlations between pattern of morphological changes on MRI and histopathological findings on muscle biopsy. The use of computer aided diagnostics to enable quantification of muscle pathology will be a welcome development for future studies and trials. New studies highlight that muscle US could be a particularly useful point of care tool in longitudinal monitoring of patients with active myositis. Muscle FDG-PET scan shows inflammatory activity in IIM muscle and can also provide additional information on extra-muscular manifestations and cancer screening. Utilization of novel tracers is an exciting development for IIM evaluation. Muscle MRI remains the gold standard for muscle imaging in IIM. Growing literature on muscle US and PET scan highlight their promising applications in IIM.

Identifiants

DOI: 10.1097/BOR.0000000000001043 PMID: 39171605

pubmed: 39171605

doi: 10.1097/BOR.0000000000001043

pii: 00002281-990000000-00137

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers 2021; 7:86.

Lundberg IE, Miller FW, Tjärnlund A, Bottai M. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med 2016; 280:39–51.

de Visser M, Carlier P, Vencovsky J, et al. 255th ENMC workshop: muscle imaging in idiopathic inflammatory myopathies. 15th January, 16th January and 22nd January 2021 – virtual meeting and hybrid meeting on 9th and 19th September 2022 in Hoofddorp, The Netherlands. Neuromuscul Disord 2023; 33:800–816.

Fraser DD, Frank JA, Dalakas M, et al. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991; 18:1693–1700.

Fleckenstein JL, Canby RC, Parkey RW, Peshock RM. Acute effects of exercise on MR imaging of skeletal muscle in normal volunteers. AJR Am J Roentgenol 1988; 151:231–237.

Kamath S, Venkatanarasimha N, Walsh MA, Hughes PM. MRI appearance of muscle denervation. Skeletal Radiol 2008; 37:397–404.

Kim JH, Kim YJ, Koh SH, et al. Rhabdomyolysis revisited: detailed analysis of magnetic resonance imaging findings and their correlation with peripheral neuropathy. Medicine 2018; 97:e11848.

Marth AA, Hosse C, Yamamura J, et al. The value of nonenhanced MRI in the evaluation of patients with suspected idiopathic inflammatory myopathy. Muscle Nerve 2024; 69:334–339.

Elessawy SS, Abdelsalam EM, Abdel Razek E, Tharwat S. Whole-body MRI for full assessment and characterization of diffuse inflammatory myopathy. Acta Radiol Open 2016; 5:2058460116668216.

Malattia C, Damasio MB, Madeo A, et al. Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Ann Rheum Dis 2014; 73:1083–1090.

Sreelal T, Bhatia A, Suri D, et al. Whole-body MR imaging in evaluation of children with juvenile dermatomyositis. Eur J Radiol 2022; 155:110475.

Filli L, Maurer B, Manoliu A, et al. Whole-body MRI in adult inflammatory myopathies: do we need imaging of the trunk? Eur Radiol 2015; 25:3499–3507.

Huang ZG, Gao BX, Chen H, et al. An efficacy analysis of whole-body magnetic resonance imaging in the diagnosis and follow-up of polymyositis and dermatomyositis. PLoS One 2017; 12:e0181069.

Zierer LK, Naegel S, Schneider I, et al. Quantitative whole-body muscle MRI in idiopathic inflammatory myopathies including polymyositis with mitochondrial pathology: indications for a disease spectrum. J Neurol 2024; 271:3186–3202.

Warman Chardon J, Díaz-Manera J, Tasca G, et al. MYO-MRI diagnostic protocols in genetic myopathies. Neuromuscul Disord 2019; 29:827–841.

Kimura M, Aizawa A, Kudou R, et al. Differences in muscle magnetic resonance imaging findings between antisignal recognition particle antibody-positive myopathy and antiaminoacyl-tRNA synthetase antibody-positive myositis. Clin Exp Rheumatol 2024; 42:321–328.

Ukichi T, Yoshida K, Matsushima S, et al. MRI of skeletal muscles in patients with idiopathic inflammatory myopathies: characteristic findings and diagnostic performance in dermatomyositis. RMD Open 2019; 5:e000850.

Yoshida K, Kurosaka D, Joh K, et al. Fasciitis as a common lesion of dermatomyositis, demonstrated early after disease onset by en bloc biopsy combined with magnetic resonance imaging. Arthritis Rheum 2010; 62:3751–3759.

Gramegna LL, Rinaldi R, Belotti LMB, et al. Magnetic resonance imaging scoring system of the lower limbs in adult patients with suspected idiopathic inflammatory myopathy. Neurol Sci 2024; 45:3461–3470.

Shimoyama T, Yoshida K, Muro Y, et al. Magnetic resonance imaging patterns revealing muscle pathology and clinical features in idiopathic inflammatory myopathies. Rheumatology 2024; doi:10.1093/rheumatology/keae125. [Online ahead of print].

doi: 10.1093/rheumatology/keae125.

Nagawa K, Suzuki M, Yamamoto Y, et al. Texture analysis of muscle MRI: machine learning-based classifications in idiopathic inflammatory myopathies. Sci Rep 2021; 11:9821.

Tasca G, Monforte M, De Fino C, et al. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve 2015; 52:956–962.

Lilleker JB, Naddaf E, Saris CGJ, et al. 272nd ENMC international workshop: 10 Years of progress – revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16–18 June 2023, Hoofddorp, The Netherlands. Neuromuscul Disord 2024; 37:36–51.

Engelke K, Chaudry O, Gast L, et al. Magnetic resonance imaging techniques for the quantitative analysis of skeletal muscle: state of the art. J Orthop Translat 2023; 42:57–72.

Ma J. Dixon techniques for water and fat imaging. J Magn Reson Imaging 2008; 28:543–558.

Ansari B, Salort-Campana E, Ogier A, et al. Quantitative muscle MRI study of patients with sporadic inclusion body myositis. Muscle Nerve 2020; 61:496–503.

Laurent D, Riek J, Sinclair CDJ, et al. Longitudinal changes in MRI muscle morphometry and composition in people with inclusion body myositis. Neurology 2022; 99:e865–e876.

Albayda J, Hayes LR, Christopher-Stine L. Dancing muscles: the value of real-time ultrasound evaluation of muscle in myositis and mimics. Rheumatology (Oxford) 2021; 60:e275–e276.

Albayda J, van Alfen N. Diagnostic value of muscle ultrasound for myopathies and myositis. Curr Rheumatol Rep 2020; 22:82.

Pulkovski N, Schenk P, Maffiuletti NA, Mannion AF. Tissue Doppler imaging for detecting onset of muscle activity. Muscle Nerve 2008; 37:638–649.

Smith E, Azzopardi C, Thaker S, et al. Power Doppler in musculoskeletal ultrasound: uses, pitfalls and principles to overcome its shortcomings. J Ultrasound 2021; 24:151–156.

Heckmatt JZ, Leeman S, Dubowitz V. Ultrasound imaging in the diagnosis of muscle disease. J Pediatr 1982; 101:656–660.

Yoshida T, Yamazaki H, Nishimori Y, et al. Correlation of muscle ultrasound with clinical and pathological findings in idiopathic inflammatory myopathies. Muscle Nerve 2023; 68:39–47.

Mamyrova G, McBride E, Yao L, et al. Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM). Rheumatology (Oxford) 2022; 61 (si):Si48–si55.

Albayda J, Christopher-Stine L, Bingham Iii CO, et al. Pattern of muscle involvement in inclusion body myositis: a sonographic study. Clin Exp Rheumatol 2018; 36:996–1002.

Walter AW, Lim J, Raaphorst J, et al. Ultrasound and MR muscle imaging in new onset idiopathic inflammatory myopathies at diagnosis and after treatment: a comparative pilot study. Rheumatology 2022; 62:300–309.

Paramalingam S, Needham M, Bulsara M, et al. The longitudinal study of muscle changes with ultrasound: differential changes in idiopathic inflammatory myopathy subgroups. Rheumatology (Oxford) 2024; 63:490–497.

Paramalingam S, Needham M, Mastaglia FL, Keen HI. A longitudinal study using B mode ultrasound and power Doppler as monitoring imaging tools in inclusion body myositis. Clin Exp Rheumatol 2024; 42:351–357.

Conticini E, Falsetti P, Al Khayyat SG, et al. A novel grey scale and Power Doppler ultrasonographic score for idiopathic inflammatory myopathies: Siena Myositis Ultrasound Grading Scale. Rheumatology (Oxford) 2021; 61:185–194.

Yoshida K, Nishioka M, Matsushima S, et al. Power Doppler ultrasonography for detection of increased vascularity in the fascia: a potential early diagnostic tool in fasciitis of dermatomyositis. Arthritis Rheumatol 2016; 68:2986–2991.

Leeuwenberg KE, van Alfen N, Christopher-Stine L, et al. Ultrasound can differentiate inclusion body myositis from disease mimics. Muscle Nerve 2020; 61:783–788.

Karvelas KR, Xiao T, Langefeld CD, et al. Assessing the accuracy of neuromuscular ultrasound for inclusion body myositis. Muscle Nerve 2019; 59:478–481.

Molina E, Albayda J. Getting under the skin: ultrasound in dermatomyositis. Scand J Rheumatol 2021; 50:497–499.

Burlina P, Billings S, Joshi N, Albayda J. Automated diagnosis of myositis from muscle ultrasound: exploring the use of machine learning and deep learning methods. PLoS One 2017; 12:e0184059.

Nodera H, Sogawa K, Takamatsu N, et al. Texture analysis of sonographic muscle images can distinguish myopathic conditions. J Med Invest 2019; 66:237–247.

Burlina P, Joshi N, Billings S, et al. Deep embeddings for novelty detection in myopathy. Comput Biol Med 2019; 105:46–53.

Mian M, Lim BG, Hossain MN, et al. Retrospective comparison of ultrasound guided percutaneous and open skeletal muscle biopsies. Intern Med J 2023; 53:1383–1389.

Connell P, Koh WS, Vonberg F, et al. The utility and tolerability of ultrasound guided muscle biopsy in the investigation of myopathy: a follow-up study. J Ultrasound 2023; 26:793–797.

Raithatha A, Ashraghi MR, Lord C, et al. Ultrasound-guided muscle biopsy: a practical alternative for investigation of myopathy. Skeletal Radiol 2020; 49:1855–1859.

Grayson PC, Alehashemi S, Bagheri AA, et al. (18) F-Fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol 2018; 70:439–449.

Parida GK, Roy SG, Kumar R. FDG-PET/CT in skeletal muscle: pitfalls and pathologies. Semin Nucl Med 2017; 47:362–372.

Karunanithi S, Soundararajan R, Sharma P, et al. Spectrum of physiologic and pathologic skeletal muscle 18F-FDG uptake on PET/CT. Am J Roentgenol 2015; 205:W141–W149.

Matuszak J, Blondet C, Hubelé F, et al. Muscle fluorodeoxyglucose uptake assessed by positron emission tomography–computed tomography as a biomarker of inflammatory myopathies disease activity. Rheumatology 2019; 58:1459–1464.

Bentick G, Fairley J, Nadesapillai S, et al. Defining the clinical utility of PET or PET-CT in idiopathic inflammatory myopathies: a systematic literature review. Semin Arthritis Rheum 2022; 57:152107.

Girija MS, Tiwari R, Vengalil S, et al. PET-MRI in idiopathic inflammatory myositis: a comparative study of clinical and immunological markers with imaging findings. Neurol Res Pract 2022; 4:49.

Motegi SI, Fujiwara C, Sekiguchi A, et al. Clinical value of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. J Dermatol 2019; 46:213–218.

Lilleker JB, Hodgson R, Roberts M, et al. [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Ann Rheum Dis 2019; 78:657–662.

Maetzler W, Reimold M, Schittenhelm J, et al. Increased [<sup>11</sup>C]PIB-PET levels in inclusion body myositis are indicative of amyloid β deposition. J Neurol Neurosurg Psychiatry 2011; 82:1060–1062.

Noto YI, Kondo M, Tsuji Y, et al. Diagnostic value of muscle [(11)C] PIB-PET in inclusion body myositis. Front Neurol 2019; 10:1386.

Quinn C, Moulton K, Farwell M, et al. Imaging with PET/CT of diffuse CD8 T-cell infiltration of skeletal muscle in patients with inclusion body myositis. Neurology 2023; 101:e1158–e1166.

Wu J, Qiu L, Wang Y, Zhang C. Dermatomyositis on 68Ga-FAPI PET/CT in a patient with nasopharyngeal carcinoma. Clin Nucl Med 2022; 47:149–150.

Ye Z, Yao Y, Yin J, et al. Detection of occult neoplasia in a patient with dermatomyositis using [(18)F]AlF-NOTA-FAPI-04 and (18)F-FDG PET/CT imaging. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2024; 43:119–120.

Li J, Wei W, Xu W, et al. [(68)Ga]Ga-FAPI-04 and [(18)F]FDG PET/CT in a patient with MDA5 dermatomyositis. Eur J Nucl Med Mol Imaging 2023; 50:3790–3791.

Zheng J, Chen H, Lin K, et al. [(68)Ga]Ga-FAPI and [(18)F]FDG PET/CT images in a patient with juvenile polymyositis. Eur J Nucl Med Mol Imaging 2021; 48:2051–2052.